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Abstract
Tuberculosis (TB) caused by Mycobacterium bovis and closely related members of the Mycobacterium tuberculosis complex
continues to affect humans and animals worldwide and its control requires vaccination of wildlife reservoir species such as
Eurasian wild boar (Sus scrofa). Vaccination efforts for TB control in wildlife have been based primarily on oral live BCG
formulations. However, this is the first report of the use of oral inactivated vaccines for controlling TB in wildlife. In this
study, four groups of 5 wild boar each were vaccinated with inactivated M. bovis by the oral and intramuscular routes,
vaccinated with oral BCG or left unvaccinated as controls. All groups were later challenged with a field strain of M. bovis. The
results of the IFN-gamma response, serum antibody levels, M. bovis culture, TB lesion scores, and the expression of C3 and
MUT genes were compared between these four groups. The results suggested that vaccination with heat-inactivated M.
bovis or BCG protect wild boar from TB. These results also encouraged testing combinations of BCG and inactivated M. bovis
to vaccinate wild boar against TB. Vaccine formulations using heat-inactivated M. bovis for TB control in wildlife would have
the advantage of being environmentally safe and more stable under field conditions when compared to live BCG vaccines.
The antibody response and MUT expression levels can help differentiating between vaccinated and infected wild boar and
as correlates of protective response in vaccinated animals. These results suggest that vaccine studies in free-living wild boar
are now possible to reveal the full potential of protecting against TB using oral M. bovis inactivated and BCG vaccines.
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Introduction
Tuberculosis (TB) caused by Mycobacterium bovis and closely
related members of the Mycobacterium tuberculosis complex (MTBC) is
a chronic disease that causes huge losses to the cattle industry [1],
has consequences on wildlife management and conservation [2],
and is a zoonosis affecting millions of people, mainly in developing
countries where it causes 10% of human TB cases [3]. The
increase in the incidence of bovine TB in some developed
countries is thought to be due, at least in part, to wildlife reservoirs
of M. bovis [1,4]. The native Eurasian wild boar (Sus scrofa) is
regarded as one of the main wildlife reservoirs of MTBC in the
Iberian Peninsula [5–6]. Moreover, wild boar TB is increasingly
recorded in other parts of its geographical range [7–8], and feral
pig TB is also a concern in countries such as New Zealand and
USA [9]. Complete depopulation is normally not an option in the
native range of this species, and culling has only transient effects
on infection prevalence (unpublished results). Effective wild boar
proof fencing of livestock pastures is costly and might cause
conflicts with conservationists due to the barrier effect [10].
Hence, wildlife vaccination to reduce MTBC infection prevalence
could become a valuable alternative or complementary tool in TB
control [11].
Wildlife vaccination for TB control is being studied worldwide
in several host reservoir models, including the brushtail possum
(Trichosurus vulpecula), ferret (Mustela furo) and red deer (Cervus
elaphus) in New Zealand [12–14], White-tailed deer (Odocoileus
virginianus) in the USA [15], African buffalo (Syncerus caffir) in South
Africa [16] and Eurasian wild boar (Sus scrofa) in Spain [17],
among others. In the United Kingdom and the Republic of
Ireland, vaccination of Eurasian badgers (Meles meles) is seen today
as a key element in a long-term strategy to eradicate the disease
from cattle [18]. The vaccine used in all these experiments is BCG
(Bacille Calmette–Gue´rin), an avirulent live strain of M. bovis. In
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wild brushtail possums, BCG was found to prevent infection and
had high (69–95%) protective efficacy [14,19]. Badgers have also
been successfully vaccinated in the field by administering BCG by
the intramuscular route. Vaccination reduced the incidence of
positive serological test results by 74% [20]. In African buffaloes,
oral BCG produced 33% reduction in lesion scores in a study
carried out in an open-air enclosure [16]. The oral delivery of baits
containing BCG to wild boar in experimental conditions allowed
reduction of M. bovis infection by 50% and lesion scores by 56%
after challenge with M. bovis [17]. At the molecular level, oral BCG
immunization of wild boar resulted in the upregulation of
immunoregulatory genes such as interferon gamma (IFN-gamma),
regulated on activation, normal T expressed and secreted cyto-
kine, also known as CCL5 (RANTES), methylmalonyl coenzyme
A mutase (MUT), complement component 3 (C3) and interleukin
4 (IL-4) that may be associated with protective response to M. bovis
infection in this species [17,21–23].
Vaccination against TB has been studied in human tuberculosis
and in several animal models with live mycobacteria such as BCG,
BCG recombinants and other mutant strains, DNA or protein
subunit vaccines, and inactivated (heat- or formalin-killed) vaccines
[24–27]. Several organisms including M. bovis BCG, the leprosy
vaccine Mycobacterium w, and Mycobacterium vaccae have also been used
in the form of inactivated vaccines [28–32]. In guinea pigs, formalin-
inactivated BCG mixed with non-phospholipid liposome adjuvants
and administered as a single subcutaneous inoculation conferred a
significant survival advantage against lethal aerogenic challenge with
M. bovis [28]. In cattle however, killed BCG in a mineral-oil adjuvant
did not evoke protective immunity [12]. In possums it has been tested
if oral killed BCG would adversely affect subsequent vaccination with
live BCG, finding that protection was not adversely affected
compared to live BCG administered orally [29].
Regarding M. w, significantly higher IFN-gamma production
was observed in mice immunized with heat-killed organisms by the
subcutaneous route than in unvaccinated controls [30]. However,
both IFN-gamma production and protection levels were consis-
tently better in live M. w vaccinated mice than in those vaccinated
with heat-killed M. w [30]. A vaccination study with heat-killed M.
w in India provided evidence suggesting protective efficacy of M. w
against pulmonary TB in humans [31]. Preventive immunization
with whole inactivated M. vaccae conferred protection against HIV-
associated TB in BCG-immunized human adults [32]. However,
intradermal vaccination with 109 heat-killed M. vaccae did not
protect cattle against an experimental challenge with M. bovis and
induced only weak cell-mediated immune responses to bovine
PPD [33]. Heat-inactivated killed M. vaccae administered intrana-
sally/intraconjunctivally to possums induced minimal protection
compared to the combination of killed M. vaccae and live BCG by
the same route [34]. However, to the best of our knowledge there
is no peer-reviewed information regarding the single use of oral
inactivated vaccines for controlling TB in wildlife. These vaccine
formulations for TB control in wildlife would have the advantage
of being environmentally safe and more stable under field
conditions when compared to live BCG vaccines.
In this study, we hypothesized that wild boar orally and
parenterally immunized with inactivated M. bovis will produce an
antibody response similar to oral live BCG vaccination and natural
M. bovis infection, but that protection against a challenge with an M.
bovis field strain, as well as the gene expression and IFN-gamma
response would be different using inactivated M. bovis and BCG. To
test this hypothesis, four groups of 5 wild boar each were vaccinated
with inactivated M. bovis by the oral and intramuscular routes,
vaccinated with oral BCG, or left unvaccinated as controls. All
groups were later challenged with a field strain of M. bovis. The
results of the IFN-gamma response, serum antibody levels, M. bovis
culture, TB lesion scores, and the expression of C3 and MUT genes
were compared between these four groups.
Materials and Methods
1. Animals and experimental design
Twenty 3-4-month-old wild boar piglets were bought in a
commercial farm known to be free of mycobacterial lesions at
slaughter and with a fully negative ELISA test [35]. The animals
were housed in class III bio-containment facilities where they had
ad libitum food and water. Wild boar piglets were randomly
assigned to one of four treatment groups: Group 1, unvaccinated
controls; Group 2, parenterally vaccinated with heat-inactivated
M. bovis; Group 3, orally vaccinated with heat-inactivated M. bovis;
Group 4, orally vaccinated with live BCG. Oral vaccines were
delivered in baits designed for wild boar piglets [36]. For the
challenge, 5 ml of a suspension containing 106 colony forming
units (cfu) of an M. bovis field strain were administered by the
oropharyngeal route as described in previous experiments [17,37].
The animals were handled nine times during the experiment,
including the vaccination (T1, day 1), the challenge two months
after vaccination (T2, day 60), and the necropsy four months after
challenge and six months after vaccination (T3, day 189). In
addition to T1, T2 and T3, blood samples were taken at days 8,
21, and 49 post-vaccination (p.v), and after challenge at days 74,
83, 104 and 133 p.v.
Handling procedures and sampling frequency were designed to
reduce stress and health risks for subjects, according to European
(86/609) and Spanish laws (R.D. 223/1988, R.D. 1021/2005).
The protocol was approved by the Committee on the Ethics of
Animal Experiments of the Regional Agriculture Authority
(Diputacio´n Foral de Vizcaya, Permit Number: 2731-2009).
2. Preparation of inactivated vaccines
The M. bovis strain used was a first passage level culture isolated
from a naturally infected wild boar in Coletsos medium. The
isolate was propagated in Middlebrook 7H9 broth enriched with
OADC for 2–3 weeks. Cells were harvested by centrifugation at
2500 x g for 20 minutes and washed twice in PBS. The bacterial
pellet was re-suspended in PBS and declumped using a fine needle
syringe. The turbidity of this suspension was adjusted to an optical
density of 1 McFarland unit. Before inactivation, tenfold serial
dilutions were prepared and plated in agar-solidified 7H9 with
OADC in quadruplicate to assess the number of cfu in the
inoculum. The inoculum was then inactivated in a water bath at
80uC for 30 minutes. Animals in ‘‘parenteral inactivated vaccine’’
and ‘‘oral inactivated vaccine’’ groups were administered with
approximately 66106 bacteria according to cfu counts. The
parenteral vaccine (1 ml) was prepared using Montanide ISA
50 V, an oily adjuvant of mannide oleate and mineral oil (Seppic,
Castres, France). The oral vaccine consisted of 2 ml of PBS
containing the inactivated mycobacteria. This inactivated vaccine
was again cultured in duplicate to assure absence of viable M. bovis.
3. BCG vaccine
The M. bovis BCG Danish reference strain (CCUG 27863) was
kindly provided by C. Martı´n (Universidad de Zaragoza, Spain). It
was cultured on Coletsos medium (Biomerieux, France), an egg
yolk medium without glycerol, and colonies from the slant were
scraped and transferred to a sterile tube containing 8–10 glass
beads. The suspension was mixed in a vortex for a few seconds and
sterile distilled water was added. Then it was allowed to settle for
5 min. The supernatant was adjusted with water to turbidity equal
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to 1.0 McFarland standard. To calculate the amount of BCG cfu
per bait, dilutions from 1021 to 1026 were prepared and 0.150
ml from each dilution were cultured in Coletsos medium in
duplicate. The tubes were cultured at 37uC and cfu readings were
taken after 5 weeks. Each bait contained 0.150 ml of the 1.0
McFarland standard.
4. Necropsy, sample collection and histopathology
Wild boar were anesthetized by intramuscular injection of
zoletil, and euthanized by captive bolt. A thorough postmortem
examination was done to detect the presence of macroscopic
lesions. Samples for culture were immediately processed and
copies frozen at 280uC for mRNA isolation. After taking out
pieces for mRNA, all main lymph nodes (LNs) and the tonsils were
serially sliced into 1–2 mm thick slices and carefully inspected for
visible TB-compatible lesions. Visceral organs were also carefully
inspected, and each lung lobe was considered separately. These
TB-compatible lesions were classified based on lesion distribution
and lesion intensity, and scored as previously described [17].
Samples of individual tissues were fixed in 10% buffered
formalin, embedded in paraffin, sectioned at 4 mm, and stained
with hematoxylin–eosin by use of standard procedures. An
additional section of those tissues with lesions indicative of
tuberculosis was stained by Ziehl–Neelsen (ZN) procedure to
detect the presence of acid-fast organisms (AFO).
5. Microbiology
The tissues collected were as follows: head lymphoid tissues
including the oropharyngeal tonsil and both mandibular, parotid,
and retropharyngeal lymph nodes (LNs); lung (each lobe),
tracheobronchial LNs and mediastinal LN; spleen, ileocaecal valve,
and mesenteric and hepatic LNs. When suspicious lesions were
observed in liver, kidney and LNs from other locations, samples
from these tissues were also cultured. Samples were thoroughly
homogenized in sterile distilled water (2 g in 10 ml or equivalently).
Five ml of this suspension was decontaminated and processed
following the instructions of the manufacturer to inoculate BBL
MGIT tubes supplemented with BBL MGIT PANTA and
BACTEC MGIT growth supplement (Becton Dickinson). BBL
tubes were incubated for 42 days in a BACTEC MGIT 960 System.
The remaining 5 ml were decontaminated in hexadecyl-pyridinium
chloride at a final concentration of 0.75% (w/v) for 12–18 h.
Samples were centrifuged at 2500 x g for 5 min and pellets cultured
in Coletsos tubes (bioMe`rieux) at 37uC for 4 months. All isolates
were spoligotyped in order to confirm the strain [38].
We defined a culture score for M. bovis infection in wild boar, as
the number of lymph node or organ samples yielding a M. bovis
isolate, of the total number of culture attempts (N$17 samples
cultured per wild boar; score range 0–17). Infection level of
samples was categorized according to the number of colonies per
tube as follows: less than 10 colonies, between 10 and 50 colonies
and more than 50 colonies.
6. bPPD ELISA test
Serum samples were tested for anti-PPD immunoglobulin G
(IgG) antibodies by means of an in-house ELISA using bovine
tuberculin purified protein derivative (bovine PPD; CZ Veter-
inaria SL, Porrin˜o, Lugo, Spain) as antigen and protein G
horseradish peroxidase (Sigma-Aldrich Quı´mica SA, Madrid,
Spain) as a conjugate applying the protocol described by Boadella
et al. [35]. Sample results were expressed as an ELISA percentage
(E%) that was calculated using the formula [Sample E% =
(sample OD/2 6 mean negative control OD) 6100]. Samples
with E%.100 were considered positive.
7. Dual-path platform (DPP) TB test
The DPP technology was developed by Chembio Diagnostic
Systems, Inc. using selected M. bovis antigens. Serum samples were
tested as previously described [39] and results were read 20
minutes after adding sample buffer. The presence and intensity of
either of the 2 separate test lines (T1, MPB83 antigen; T2,
CFP10/ESAT-6 fusion protein) were evaluated by a DPP optical
reader (in relative light units, RLU) [35].
8. Interferon gamma test
Blood samples were collected into tubes with lithium heparin
and shipped to the laboratory at room temperature. Stimulation of
whole blood with PBS (nil control), and the avian and bovine
purified protein derivative (PPD; CZ Veterinaria, Porrin˜o, Spain)
was performed within 8 h of collection as described for other
species [40–42]. Detection of IFN-gamma in the supernatant was
performed using a quantitative ELISA (Pierce Endogen, Rockford,
IL, USA) following manufacturer’s recommendations.
9. Gene expression analysis by real-time RT-PCR
The immunoregulatory genes, complement component 3 (C3)
and methylmalonyl-CoA mutase (MUT) were selected for analysis
based on their association with wild boar resistance to natural M.
bovis infection and protection against M. bovis challenge in BCG-
vaccinated wild boar [6,17,21–22].
Total RNA was extracted from peripheral blood mononuclear
cells (PBMC) using TriReagent (Sigma, Madrid, Spain) following
manufacturer’s recommendations. The RNA yield and quality were
assessed using the Experion Bioanalyzer (Bio-Rad, Madrid, Spain).
Gene-specific oligonucleotide primers were designed and used for
quantitative real-time RT-PCR (qRT-PCR) [17]. The qRT-PCR
was performed in 25 ml reaction volumes with 12.5 ml SYBR Green
iScriptH (Bio-Rad). Amplification conditions consisted of 95uC for
1 min, followed by 40 cycles of 95uC for 15 s and 55uC for 60 s. A
dissociation curve was run at the end of the reaction to ensure that
only one amplicon was formed and that the amplicon denatured
consistently in the same temperature range for every sample [43].
All reactions were performed in triplicate. Oligonucleotide primers
were used to amplify the S. scrofa cyclophilin (Genbank accession
number AY008846) as a control gene to normalize expression data
[21]. Control reactions were performed using the same procedures,
but without RT to monitor DNA contamination in the RNA
preparations and without RNA added to monitor contamination of
the PCR reaction. The mRNA values were normalized against S.
scrofa cyclophilin gene expression using the 2-DDCt method [44].
Table 1. Body weight, head and body length, and kidney fat
index (KFI) at necropsy for wild boar belonging to four
experimental groups (mean 6 SE).
Group
Body
weight (kg)
Body
length (cm) KFI (%)
Control 18.4262.5 88.8662.6 19.5267.4
Parenteral inactivated 25.6762.5 102.5462.6 25.4166.6
Oral inactivated 28.0462.3 103.5062.9 31.7666.6
Oral BCG 20.6662.3 93.5862.6 29.9166.6
Differences among groups were significant for weight (F3, 14 = 3.4, p,0.05) and
for head and body length (F3, 15 = 6.9, p,0.01), but not for the KFI (F3, 15 = 0.6,
p.0.05). Post hoc Tukey tests revealed significant differences only for head and
body length between the control group and the two inactivated vaccinated
groups (p = 0.01).
doi:10.1371/journal.pone.0024905.t001
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The normalized expression was calculated at each time point and
the mean of triplicate values was used to compare data between
vaccinated and control groups.
10. Statistical analyses
Normal data such as body weight, head and body length, and
kidney fat were compared by analysis of variance (ANOVA)
followed by a series of Tukeys post-hoc tests for pair comparisons
(p = 0.05). Regression was used to analyze the relation between
lesion scores and serum antibody levels. Chi square tests were used
to compare proportions. Lesion scores and culture scores were
compared among groups with the non-parametric median test.
Results
1. Clinical signs and body condition
All animals were observed daily throughout the experiment and
TB signs were not detected. At necropsy, all wild boar were
measured, weighted, and the kidney fat index (KFI) calculated.
Control wild boar consistently had the lowest values, and the
Figure 1. Wild boar TB lesion scores at necropsy. Total lesion score (upper panel) and thorax lesion score (lower panel) for 20 wild boar used in
the vaccination and challenge experiments. The solid lines show the median values. In the lower panel, solid squares indicate animals with massive
Mycobacterium bovis growth (.50 colonies) from thoracic samples.
doi:10.1371/journal.pone.0024905.g001
Inactivated Tuberculosis Vaccine
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difference among groups was significant for weight and for head
and body length, but not for the KFI (Table 1).
2. Pathology
Total lesion, head lesion and thorax lesion scores were highest
in the control group (Figure 1). The mean lesion score for control
wild boar was 1863. In the parenteral inactivated, oral inactivated
and oral BCG groups we observed a reduction of the mean lesion
score by 43.3%, 43.3% and 52.2%, respectively. One control wild
boar presented the most severe lung lesions showing extensive
areas of pneumonia involving the cranial, middle and right caudal
and left middle lobes, along with both tracheobronchial LNs
(Table 2). The reduction of the mean thorax lesion score as
compared to the controls was of 84.8%, 75.7% and 69.7%,
respectively.
Two controls and one oral inactivated vaccinated wild boar had
AFO in lung tissues. These were not recorded in the parenteral
inactivated and BCG vaccinated wild boar. Differences in total
and thorax lesion scores were not significant (Median test, Chi2
#5.45; p.0.05).
3. M. bovis isolation
Total culture scores and thorax culture scores were again
highest in the control group (4.460.7 and 0.660.2, respectively).
All isolates belonged to the field M. bovis strain used for challenge.
In the parenteral inactivated, oral inactivated and oral BCG
groups we observed almost no reduction of the mean culture score:
4.5%, 9% and 9%, respectively. However, the reduction of the
mean thorax culture score as compared to the controls was of
66.7%, 33.3% and 66.7%, respectively. Moreover, massive M.
bovis growth on solid media (.50 colonies) was observed among 3/
5 controls, 2/5 parenterally vaccinated, and none of 5 oral
inactivated and 5 oral BCG vaccinated wild boar, respectively.
Tissues where massive growth occurred included thoracic LNs in
the three controls (tracheobronchial LN in two cases and
mediastinic LN in one), but only head LNs (mandibular and
retropharyngeal) in the parenterally vaccinated ones (Figure 1).
Differences in total and thorax culture scores were not significant
(Median test, Chi2 #2.42; p.0.05).
4. Serum antibody response
Figure 2 presents the mean antibody responses per treatment
group. Regarding bPPD, antibody levels were consistently low
during the experiment and increased only late after challenge in all
groups except the oral BCG one (time F6, 112 = 6.92, p,0.001;
group F3, 112 = 2.62, p.0.05; interaction F18, 112 = 0.72, p.0.05).
DPP-T1 reactivity changed significantly in time (F6, 112 = 23.7,
p,0.001) and among groups (F3, 112 = 45.2, p,0.001), and the
interaction between time and group was also significant (F3, 112
= 2.62, p,0.05), essentially because the parenterally inactivated
vaccinated wild boar responded to MPB83 antigen immediately
after vaccination, in contrast to the orally vaccinated ones and the
controls. No significant differences were observed regarding
antibody reactivity with CFP10/ESAT-6 in the DPP assay
(F,2, p.0.05 in all cases). Thus, the serologic tests allowed
differentiating vaccinated not challenged from vaccinated chal-
lenged wild boar after a period of time post inoculation, if the
vaccine was administered parenterally. The former responded to
MPB83 and not to bPPD, while the latter (after challenge)
responded to both bPPD and MPB83.
At necropsy, the differences among groups in serum antibody
levels were not significant (bPPD: F3, 16 = 0.87; DPP-T1: F3, 16
= 1.68; DPP-T2: F3, 16 = 1.37; p.0.05). However, the oral BCG
group tended to have the lowest responses to bPPD and to
CFP10/ESTA-6 antigen, while the parenteral inactivated vaccine
group had the highest responses to bPPD and to MPB83 protein.
Control wild boar had the highest response to CFP10/ESAT-6
antigen in DPP assay (Table 3).
We observed a statistically significant positive relationship
between the bPPD ELISA values and total lesion scores of the
20 challenged wild boar (R2 = 0.38, p,0.01; Figure 3).
5. Interferon gamma response
Figure 4 presents the mean OD readings of the four treatment
groups regarding IFN-gamma production in response to bPPD.
All tested negative to IFN-gamma at T1, mean levels being nil
(mean OD 0.131). All PBS controls also yielded consistently low
results (OD,0.227). Forty-eight days after vaccination, only the
parenterally vaccinated group showed a clear and homogeneous
IFN-gamma response. Two wild boar of the oral BCG vaccinated
group also responded to a lesser extent. One week after challenge,
the picture remained as after vaccination. However, at day 21
after challenge all wild boar showed high IFN-gamma responses
which were maintained until necropsy at T3 (OD.0.291). Again,
the mean response stayed highest in the parenterally vaccinated
group (F3,16 = 3.88, p,0.05). Post hoc Tukey tests revealed
significant differences only between parenterally vaccinated and
oral BCG vaccinated wild boar (p = 0.02). The IFN-gamma OD at
T3 was correlated with the number of ZN positive tissues
(rs = 0.44, n = 20, p,0.05). We found no other correlation
between IFN-gamma responses and culture or lesion scores
(p.0.05).
6. Gene expression response to vaccination
The C3 and MUT mRNA levels were analyzed in PBMC at
time points T1 (before vaccination), T2 (2 months after
Table 2. Summary of pathology findings expressed as
number of animals showing macroscopic lesions, number of
animals showing only microscopic lesions, and number of
animals with AFO in Ziehl-Neelsen stained sections, separated
by bars.
Group
Organ Control
Parenteral
inactivated
Oral
inactivated Oral BCG
Tonsil 1/0/0 2/1/1 3/0/0 0/1/0
Mandibular LNa 5/0/5 5/0/3 5/0/2 5/0/2
Retropharyngeal LN 3/0/0 3/0/2 2/0/1 3/1/0
Parotid LN 1/1/0 2/0/0 1/0/1 0/1/0
Lung 2/0/1 0/1/0 2/0/1 1/1/0
Tracheobronchial LN 4/1/2 3/1/0 2/1/0 3/0/0
Mediastinal LN 1/0/0 0/0/nd 1/0/0 0/0/nd
Liver 0/0/nd 0/0/nd 0/0/nd 1/0/0
Spleen 0/0/nd 0/0/nd 0/0/nd 0/0/nd
Kidney 0/0/nd 0/0/nd 0/0/nd 0/0/nd
Ileocecal valve 0/1/0 0/0/nd 0/0/nd 0/0/nd
Hepatic LN 0/0/nd 0/0/nd 0/0/nd 1/0/0
Ileocecal LN 0/0/nd 2/0/1 0/0/nd 0/0/nd
Mesenteric LN 0/0/nd 2/0/0 0/0/nd 2/0/0
aLN: lymph node;
bnd: not done.
doi:10.1371/journal.pone.0024905.t002
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Figure 2. Serum antibody response after vaccination and after challenge. Mean serum antibody response (n = 5 for each point and group)
as measured by the bPPD ELISA (in ELISA percentage, E%) and the MPB83 dual-path platform test (DPP-T1, in relative light units, RLU).
doi:10.1371/journal.pone.0024905.g002
Table 3. Serum antibody levels at necropsy for 20 wild boar belonging to four experimental groups (mean 6 SE), as measured by
the bPPD ELISA (in ELISA percentage, E%) and the dual-path platform tests (DPP, in relative light units, RLU; DPP test 1: MPB83; DPP
test 2: CFP10/ESAT-6).
Group bPPD ELISA %E (+/2) Chembio DPP test 1 RLU (+/2) Chembio DPP test 2 RLU (+/2)
Control 247.026104 (3/2) 83.36620.7 (4/1) 31.68611.9 (2/3)
Parenteral inactivated 265.316104 (4/1) 129.74620.7 (5/0) 11.80611.9 (1/4)
Oral inactivated 195.246104 (2/3) 68.22620.7 (4/1) 4.7611.9 (2/3)
Oral BCG 50.256104 (0/5) 105.28620.7 (5/0) 0611.9 (0/5)
Chi2 3 d.f. 7.07 p.0.05 2.22 p.0.05 7.2 p.0.05
doi:10.1371/journal.pone.0024905.t003
Inactivated Tuberculosis Vaccine
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vaccination and before challenge) and T3 (at the end of the
experiment 4 months after challenge; Figures 5A and 5B). MUT
expression was similar between wild boar orally-immunized with
BCG and inactivated M. bovis and was significantly higher
(p,0.05) when compared to controls at T2 (Figure 5A). For these
groups, MUT expression levels were significantly (p,0.05) higher
at T2 than at T1 and T3 (Figure 5A). MUT expression levels in
wild boar parentally-immunized with inactivated M. bovis were
similar to controls at all time points (Figure 5A). Although the C3
expression levels were significantly (p,0.05) higher at T2 than at
T1 and T3 for wild boar orally-immunized with BCG, differences
were not observed between groups at any time point analyzed.
Discussion
The number of wild boar tested was necessarily low, and this
limited the statistical significance of the results. However, data
presented herein suggest that vaccines based on heat-inactivated
M. bovis triggered an immune response in wild boar that conferred
protection against challenge with an M. bovis field strain at a
similar level as did oral BCG. In contrast to our initial hypothesis,
this is the first report showing the potential use of inactivated M.
bovis vaccines for TB control in a wildlife species.
In order to obtain uniform results, we used a high challenge dose
of 106 cfu of M. bovis [17]. As a consequence, all vaccinated wild boar
subjected to experimental challenge became infected. However,
vaccination reduced the number and severity of lesions and the
infection burden, particularly in the thoracic region, similar to BCG
vaccination results in other wildlife species (e.g. in badgers challenged
with 104 M. bovis CFU by the endobronchial route; [18,20]). Thus,
given the severity of the challenge, the estimated protection is likely to
be an underestimate of the true vaccine effect [18].
Protection levels, antibody levels, IFN-gamma response and
MUT and C3 gene expression varied among treatments.
Unvaccinated controls responded after challenge with both
antibody and IFN-gamma production. At the time of necropsy,
controls had the poorest condition scores and the highest mean
lesion and culture scores, more thoracic tissues with AFO, as well
as the highest mean antibody response to the CFP10/ESAT-6
fusion protein. The lesions recorded in this control group were
similar to those observed in previous experiments in captivity [17],
and to those recorded in the field [45]. The finding of lower
condition scores in controls as compared to vaccinated animals
contrasts with results obtained in badgers [18]. However, badgers
used for the vaccination and challenge experiments were field-
captured adults while we used more uniform farm-bred wild boar
piglets.
It is remarkable that all wild boar responded to MPB83 (DPP-
T1) immediately after challenge and before antibodies against
bPPD raised in the ELISA test. Both techniques can potentially be
complementary to differentiate animals with recent infection (and
probably without visible lesions) from animals with more advanced
lesions. Whether the MPB83 increase is transient or not needs to
be investigated.
In contrast to all other treatments, the group vaccinated
parenterally with inactivated M. bovis had an almost immediate
MPB83 and IFN-gamma response after vaccination. This group
Figure 3. Relationship between antibody response and lesion
scores. Relationship between the level of antibodies against bPPD in
blood serum (E%) and the lesion scores of wild boar (n = 20)
experimentally challenged with Mycobacterium bovis. The regression
equation and the coefficient of determination are shown in the chart.
doi:10.1371/journal.pone.0024905.g003
Figure 4. Detection of gamma interferon. Mean optical density (OD) readings of the gamma interferon ELISA (n = 5 for each point and group).
doi:10.1371/journal.pone.0024905.g004
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maintained the highest IFN-gamma levels at necropsy. In badgers,
most individuals were also positive to IFN-gamma after parenteral
BCG vaccination [20] and in wild boar a transient increase in
IFN-gamma mRNA and serum levels were observed 5 weeks after
parenteral BCG vaccination [21]. The early and robust IFN-
gamma and MPB83 serum antibody responses, in contrast to the
less prominent responses to the bPPD ELISA test, would allow
using a combination of these tests to distinguish between
parenterally vaccinated and parenterally vaccinated/M. bovis-
infected wild boar in the field, at least until 4 months after
challenge. In vaccinated mice and possums, IFN-gamma is
considered a correlate of protective immunity [30,46]. However,
in this study we observed no correlation between IFN-gamma
response and lesion scores, except for the number of ZN positive
tissues. This lack of correlation between post vaccination cellular
immune responses and levels of protection was also observed in
orally BCG vaccinated badgers, but was not associated with a
failure of the vaccine to protect against M. bovis [18].
The group vaccinated orally with inactivated M. bovis responded
in a very similar way to the group vaccinated with oral BCG.
Lesion and culture scores were similar, although slightly lower in
the BCG group. Regarding serum antibodies and IFN-gamma
production, both groups responded only after challenge, as in
orally BCG vaccinated badgers [18]. The BCG group had the
lowest bPPD and CFP10/ESAT-6 antibody levels, suggesting less
advanced disease and/or less stimulation of the antibody response
against M. bovis. Serum antibodies have been used as a surrogate
for BCG-mediated protection against experimental [47] and
natural M. bovis infection in badgers [20]. Furthermore, our results
confirmed that the bPPD ELISA results correlate with the lesion
score in wild boar (Figure 3). These results suggest that this ELISA
may be used not only for prevalence studies, but also for classifying
infected animals as showing a more or less advanced disease, for
instance during field experiments to test the effect of vaccination
for the control of TB in wild boar.
M. bovis infection affects gene expression in wild boar [22–
23,48–50]. Some of these genes such as C3 and MUT were shown
to correlate with resistance to natural M. bovis infection and
protection against M. bovis challenge in BCG-vaccinated wild boar
[6,17,21–22]. As in previous experiments [17,21–23,50], MUT
Figure 5. Quantitative MUT and C3 gene expression analysis in PMBC using qRT-PCR. Quantitative MUT (panel A) and C3 (panel B) gene
expression analysis in PBMC of vaccinated wild boar and controls using qRT-PCR. Results were recorded as mRNA levels after normalization for
cyclophilin gene expression using the 2-DDCt method for each of the three time points (T1: before vaccination, T2: before challenge, T3: end of the
experiment). Values are shown as average 6SD.
doi:10.1371/journal.pone.0024905.g005
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mRNA levels increased with BCG vaccination and decreased after
M. bovis infection. However, the increase in MUT expression after
vaccination was significant for orally-immunized wild boar only,
suggesting differences between orally and parentally immunized
animals at least with respect to MUT expression. Although the C3
expression profile in wild boar orally-immunized with BCG was
similar to that shown before in parentally and orally BCG-
immunized wild boar [17,21], no significant differences were
observed between groups. These results provided additional
evidences for the role of MUT expression in protection against
M. bovis infection in wild boar. Although the mechanism by which
MUT expression contributes to resistance to mycobacterial
infection are unknown, a hypothesis was recently discussed to
suggest that host genetically-defined higher MUT expression levels
result in lower serum cholesterol concentration and tissue deposits
that increase the protective immune response to M. bovis, thus
resulting in resistance to bovine TB and better response to BCG
vaccination [51]. The observation that both orally vaccinated
groups had a clear increase in MUT expression after vaccination
suggested that MUT expression, in combination with serum
antibody tests, could be used to distinguish between unvaccinated/
uninfected, orally vaccinated, and infected or orally vaccinated/
infected wild boar in the field. However, a major flaw of using
killed M. bovis as vaccine would be that (parenteral) vaccination
will induce responses to antigens like ESAT6 and CFP-10. These
antigens have been suggested as DIVA antigens for BCG
vaccination [27]. Hence, wild boar immunization experiments
with killed BCG or other M. bovis variants should eventually be
considered.
Conclusions
The results reported here showed that wild boar respond
similarly to BCG and to vaccination with heat-inactivated M. bovis.
These results also encourage to test combinations of BCG and
inactivated M. bovis to vaccinate against TB in wild boar, as tested
in possums by Skinner et al. [34] with M. vaccae. Vaccine
formulations using heat-inactivated M. bovis for TB control in
wildlife would have the advantage of being environmentally safe
and more stable under field conditions as compared to live BCG
vaccines. Tools for the selective and effective delivery of baits to
wild boar piglets have been set up and field-tested with dummy
vaccines [36,52–54]. The ELISA and MUT expression tests
shown here can help differentiating between vaccinated and
infected animals and as correlates of protective response in
vaccinated wild boar. Hence, studies in free-living wildlife under
conditions of natural M. bovis transmission are now possible and
will hopefully reveal the full potential of protecting wild boar
against TB using oral M. bovis inactivated and BCG vaccines.
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